{"id":699,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1997-06-04","marketCap":7452.86328125,"name":"Sarepta Therapeutics Inc","phone":"16172744000.0","outstanding":93.27999877929688,"symbol":"SRPT","website":"https://www.sarepta.com/","industry":"Biotechnology"},"price":79.0725,"year":2023,"month":11,"day":14,"weekday":"Tuesday","title":"The Potential Consequences of Cybersecurity Breaches on Sarepta Therapeutics Inc's Stock Performance","date":"2023-11-14","url":"/posts/2023/11/14/SRPT","content":[{"section":"Introduction","text":"Sarepta Therapeutics Inc is a leading biopharmaceutical company that focuses on developing innovative therapies for rare diseases. As with any organization that deals with sensitive patient information, cybersecurity and data privacy are critical to maintaining trust among customers and stakeholders. In this article, we will delve into the potential consequences of cybersecurity breaches or data privacy issues on Sarepta Therapeutics Inc's stock performance."},{"section":"Impact on Reputation","text":"One of the immediate consequences of a cybersecurity breach or data privacy issue is the potential damage to the company's reputation. News of a breach can quickly spread through media outlets and social platforms, causing panic among customers and shareholders. The public perception of the company's ability to protect sensitive data can significantly impact its reputation and subsequently, its stock performance."},{"section":"Loss of Customer Trust","text":"Data breaches can lead to a loss of customer trust, which can have long-term implications for Sarepta Therapeutics Inc. If customers perceive that their personal information is not adequately protected, they may choose to take their business elsewhere. This loss of customer trust could result in a decline in revenue and ultimately impact the company's stock price."},{"section":"Legal and Regulatory Consequences","text":"In addition to reputational damage, cybersecurity breaches can also have legal and regulatory consequences. Depending on the severity and scope of the breach, Sarepta Therapeutics Inc may face lawsuits and fines from affected individuals or regulatory bodies. Legal battles and penalties can drain the company's resources and leave a lasting impact on its financial performance, potentially affecting stock prices."},{"section":"Investor Concerns and Market Reaction","text":"Investors are increasingly aware of the potential risks associated with cybersecurity breaches and data privacy issues. When such incidents occur, investors may become concerned about the company's ability to safeguard sensitive information and mitigate future risks. This concern could lead to a sell-off of Sarepta Therapeutics Inc's stock, causing a decline in its stock price. Additionally, stock markets are sensitive to news and events that impact the overall stability and reputation of companies, and cybersecurity breaches can trigger negative sentiment in the market, further influencing stock performance."},{"section":"Mitigating the Impact","text":"To mitigate the potential consequences of cybersecurity breaches or data privacy issues, Sarepta Therapeutics Inc should prioritize robust cybersecurity measures and invest in state-of-the-art technologies. Implementing secure data storage systems, regular vulnerability assessments, and employee training programs can help reduce the risk of breaches. Additionally, prompt and transparent communication with customers, stakeholders, and regulators in the event of a breach can help maintain trust and minimize reputational damage."},{"section":"Conclusion","text":"Cybersecurity breaches or data privacy issues can have significant consequences on Sarepta Therapeutics Inc's stock performance. The impact on reputation, loss of customer trust, legal and regulatory consequences, investor concerns, and market reactions can all contribute to a decline in the company's stock price. It is essential for Sarepta Therapeutics Inc to prioritize cybersecurity and data privacy to protect its reputation, maintain customer trust, and safeguard its stock performance."}],"tags":["CrossUnder100","Short","Biotechnology"],"news":[{"category":"company","date":1699887311,"headline":"Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock Now","id":123837974,"image":"https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9","symbol":"SRPT","publisher":"Yahoo","summary":"Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.","url":"https://finance.yahoo.com/news/heres-why-sarepta-therapeutics-srpt-145511622.html"},{"category":"company","date":1699880226,"headline":"Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Here’s Why You Should Pay Attention","id":123851545,"image":"https://media.zenfs.com/en/tipranks_452/e84ebdb57c3c31f5731dc8e5fe308863","symbol":"SRPT","publisher":"Yahoo","summary":"Seasoned investors will have different strategies to maximize returns but one way of gaining alpha in the markets is by keeping a tab on the actions of the insiders. By insiders, we’re referring to the corporate officers who sit on company boards and are responsible for their respective firms’ performances. These in-the-know types have access to information not available to the casual investor and when they are seen picking up shares of the companies they work for – to keep the playing field lev","url":"https://finance.yahoo.com/news/insiders-load-2-strong-buy-125706099.html"},{"category":"company","date":1699704660,"headline":"Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns","id":123812935,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3207749532"},{"category":"company","date":1699542000,"headline":"Is Sarepta Therapeutics Stock a Bad-News Buy?","id":123779472,"image":"","symbol":"SRPT","publisher":"Yahoo","summary":"Shares of the company crashed last week after it released results from phase 3 trials, which failed to impress investors and analysts.  Is the company in big trouble, or is this latest setback simply a good opportunity for long-term investors to buy the stock at a reduced price?  A primary endpoint is the main goal for a trial, and if that isn't met, that can be a sign it is not effective.","url":"https://finance.yahoo.com/m/b876b4ae-f02b-3f8f-b32b-a96bf1820be8/is-sarepta-therapeutics-stock.html"},{"category":"company","date":1699456500,"headline":"1 Gene Therapy Stock to Buy and Hold for the Long Haul","id":123733668,"image":"https://s.yimg.com/ny/api/res/1.2/AL66h6jjJg9Y7EYfaMoaxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/216eade86e884dce603dda721f8d45f4","symbol":"SRPT","publisher":"Yahoo","summary":"Biotech companies working on gene therapies have made significant strides lately, but many of them remain relatively risky stocks.  This factor makes biotechs focused on gene therapies attractive targets for long-term investors, provided they pick the right stocks in this niche.  With that said, let's look at one gene-therapy company that's been having a tough time of late, but is well worth investing in: Sarepta Therapeutics (NASDAQ: SRPT).","url":"https://finance.yahoo.com/m/feee6c88-74fe-398f-b2ba-33681f9c936d/1-gene-therapy-stock-to-buy.html"},{"category":"company","date":1699437916,"headline":"Insider Spends US$3.9m Buying More Shares In Sarepta Therapeutics","id":123733669,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"SRPT","publisher":"Yahoo","summary":"Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders (or potential shareholders) will be happy to see that the...","url":"https://finance.yahoo.com/news/insider-spends-us-3-9m-100516828.html"},{"category":"company","date":1699417411,"headline":"Here’s What Bronte Capital Calls “Sarepta Risk” in the Context of Sarepta Therapeutics (SRPT)","id":123733671,"image":"https://media.zenfs.com/en/insidermonkey.com/759e7b7c91438d7b6a939bbf14042f78","symbol":"SRPT","publisher":"Yahoo","summary":"Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The fund gained 9.96% last quarter (-0.44% in September) compared to 0.02% (-3.70% in September) for the MSCI ACWI (in $A). In addition, you can check the top 5 holdings of the fund […]","url":"https://finance.yahoo.com/news/bronte-capital-calls-sarepta-risk-042331839.html"},{"category":"company","date":1699357920,"headline":"Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Adverum Biotechnologies (ADVM) and Alignment Healthcare (ALHC)","id":123728509,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3201437770"},{"category":"company","date":1699357140,"headline":"8 Health Care Stocks Whale Activity In Today's Session","id":123689747,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3200013099"},{"category":"company","date":1699324320,"headline":"Noteworthy Tuesday Option Activity: SRPT, W, CORT","id":123728510,"image":"","symbol":"SRPT","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3200309442"},{"category":"company","date":1699247280,"headline":"Bank of America Securities Analyst Maintains Buy Rating for Sarepta Therapeutics Amid FDA Discussions and Potential Label Expansion","id":123666881,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3197425763"},{"category":"company","date":1699005960,"headline":"Biotech Alert: Searches spiking for these stocks today","id":123587166,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3193876948"},{"category":"company","date":1698963947,"headline":"Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Call Transcript","id":123582415,"image":"https://media.zenfs.com/en/insidermonkey.com/9c22d73976b5c49865fb84ae2148a747","symbol":"SRPT","publisher":"Yahoo","summary":"Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Call Transcript November 1, 2023 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.46, expectations were $-1.63. Operator: Good afternoon and welcome to the Sarepta Therapeutics Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be […]","url":"https://finance.yahoo.com/news/sarepta-therapeutics-inc-nasdaq-srpt-222547317.html"},{"category":"company","date":1698941880,"headline":"Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat","id":123572426,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"SRPT","publisher":"Yahoo","summary":"Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.","url":"https://finance.yahoo.com/news/sarepta-srpt-q3-loss-narrower-161800626.html"},{"category":"company","date":1698929400,"headline":"Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Sarepta Therapeutics (SRPT) and Pediatrix Medical Group (MD)","id":123594082,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3190805382"},{"category":"company","date":1698928200,"headline":"Schwartz Advocates for Sarepta Buy Rating Amidst Elevidys’ Potential and Undervalued Market Position","id":123623934,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3190790628"},{"category":"company","date":1698928200,"headline":"Sarepta Therapeutics to Present at the UBS Biopharma Conference","id":123582417,"image":"https://media.zenfs.com/en/business-wire.com/c7bf921d824ffa92416d82ab724386bd","symbol":"SRPT","publisher":"Yahoo","summary":"CAMBRIDGE, Mass., November 02, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 9:00 a.m. E.T. The fireside chat will be held at the Fontainebleau Miami Beach in Miami Beach, Fla.","url":"https://finance.yahoo.com/news/sarepta-therapeutics-present-ubs-biopharma-123000960.html"},{"category":"company","date":1698913560,"headline":"Sarepta price target raised to $93 from $82 at Needham","id":123623936,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3191262974"},{"category":"company","date":1698903600,"headline":"Sarepta price target lowered to $141 from $193 at Barclays","id":123623937,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3191031550"},{"category":"company","date":1698897634,"headline":"Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript","id":123582418,"image":"https://media.zenfs.com/en/motleyfool.com/ce68ea0b0cd2631701fe87e542e7a165","symbol":"SRPT","publisher":"Yahoo","summary":"Earlier this afternoon, we released our financial results for the third quarter of 2023.  Joining us on the call today are Doug Ingram, Ian Estepan, Dallan Murray, and Dr.  After our formal remarks, we'll open the call for Q\u0026A. I'd like to note that during this call, we will be making a number of forward-looking statements.","url":"https://finance.yahoo.com/m/b7a44981-72df-31ec-8fb1-499c9ce3cd96/sarepta-therapeutics-%28srpt%29.html"},{"category":"company","date":1698870782,"headline":"Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript","id":123553693,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"SRPT","publisher":"SeekingAlpha","summary":"Sarepta Therapeutics, Inc. (NASDAQ:NASDAQ:SRPT) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ETCompany ParticipantsFrancesca Nolan - IR...","url":"https://seekingalpha.com/article/4646166-sarepta-therapeutics-inc-srpt-q3-2023-earnings-call-transcript"},{"category":"company","date":1698870550,"headline":"Analysts on Wall Street Lower Ratings for These 10 Stocks","id":123553543,"image":"https://s.yimg.com/ny/api/res/1.2/vGZJmuHTJeZzs3i.RJRRUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/26cd8448ec46f99f9f044e0e1b3e6ec4","symbol":"SRPT","publisher":"Yahoo","summary":"In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These 5 Stocks. Headlines from the financial markets indicate a mixed landscape as stocks and Treasuries experienced upward movement in anticipation […]","url":"https://finance.yahoo.com/news/analysts-wall-street-lower-ratings-202910142.html"},{"category":"company","date":1698869745,"headline":"Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation","id":123553161,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"SRPT","publisher":"SeekingAlpha","summary":"The following slide deck was published by Sarepta Therapeutics, Inc.","url":"https://seekingalpha.com/article/4646154-sarepta-therapeutics-inc-2023-q3-results-earnings-call-presentation"},{"category":"company","date":1698869100,"headline":"Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments","id":123553544,"image":"https://media.zenfs.com/en/business-wire.com/4c54b58d3332c36ba5f3feab60c665ec","symbol":"SRPT","publisher":"Yahoo","summary":"CAMBRIDGE, Mass., November 01, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.","url":"https://finance.yahoo.com/news/sarepta-therapeutics-announces-third-quarter-200500910.html"},{"category":"company","date":1698858180,"headline":"Sarepta Therapeutics: Q3 Earnings Snapshot","id":123557463,"image":"","symbol":"SRPT","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=mv24m5vxtu"},{"category":"company","date":1698829500,"headline":"Sarepta call volume above normal and directionally bullish","id":123557465,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3189099495"},{"category":"company","date":1698828000,"headline":"Unusually active option classes on open November 1st","id":123545415,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3189061405"},{"category":"company","date":1698819900,"headline":"Sarepta price target lowered to $97 from $175 at TD Cowen","id":123557469,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3188885578"},{"category":"company","date":1698819660,"headline":"Earnings Scheduled For November 1, 2023","id":123545575,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3188881852"},{"category":"company","date":1698818520,"headline":"Sarepta Stock (NASDAQ:SRPT) Plunged 37% on Disappointing Elevidys Trial Data","id":123557471,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3188862610"},{"category":"company","date":1698817020,"headline":"Potential Elevidys Label Expansion Bolsters Buy Rating for Sarepta Therapeutics: An Analyst’s Perspective","id":123557472,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3188838526"},{"category":"company","date":1698810240,"headline":"Sarepta reports Q3 EPS 37c, consensus ($1.32)","id":123557474,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3189759391"},{"category":"company","date":1698808560,"headline":"Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M","id":123557475,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3189707028"},{"category":"company","date":1698796901,"headline":"JP Morgan Maintains Sarepta Therapeutics (SRPT) Overweight Recommendation","id":123535427,"image":"","symbol":"SRPT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/jp-morgan-maintains-sarepta-therapeutics-srpt-overweight-recommendation-863"},{"category":"company","date":1698793320,"headline":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","id":123542148,"image":"https://media.zenfs.com/en/business-wire.com/14a72b3453a578e53a83381e69da9b0d","symbol":"SRPT","publisher":"Yahoo","summary":"CAMBRIDGE, Mass., October 31, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in October 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).","url":"https://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-230200240.html"},{"category":"company","date":1698784804,"headline":"Morgan Stanley Maintains Sarepta Therapeutics (SRPT) Overweight Recommendation","id":123531082,"image":"","symbol":"SRPT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/morgan-stanley-maintains-sarepta-therapeutics-srpt-overweight-recommendation-913"},{"category":"company","date":1698784798,"headline":"Needham Maintains Sarepta Therapeutics (SRPT) Buy Recommendation","id":123529083,"image":"","symbol":"SRPT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/needham-maintains-sarepta-therapeutics-srpt-buy-recommendation-866"},{"category":"company","date":1698784798,"headline":"RBC Capital Maintains Sarepta Therapeutics (SRPT) Outperform Recommendation","id":123529082,"image":"","symbol":"SRPT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/rbc-capital-maintains-sarepta-therapeutics-srpt-outperform-recommendation-268"},{"category":"company","date":1698784798,"headline":"Cantor Fitzgerald Downgrades Sarepta Therapeutics (SRPT)","id":123529081,"image":"","symbol":"SRPT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/cantor-fitzgerald-downgrades-sarepta-therapeutics-srpt-170"},{"category":"company","date":1698783555,"headline":"Nvidia, Caterpillar, Sarepta: Trending Tickers","id":123529006,"image":"https://s.yimg.com/ny/api/res/1.2/l7bXwfTve8NVmSO7oGkGPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2023-10/8c5f39e0-7828-11ee-be3e-8877ea046578","symbol":"SRPT","publisher":"Yahoo","summary":"Nvidia (NVDA) shares trend in the red ahead of Tuesday's closing bell, recovering after slipping in the morning session on a Wall Street Journal report stating the chipmaker could lose out on $5 billion worth of orders to China due to the Biden administration's new export controls for advanced AI chips. Caterpillar (CAT) released its third-quarter earnings which beat expectations, while shares declined after the company revised and lowered guidance on its 2024 outlook due to weakened international demand. The company also has a $2 billion decline in its backlog compared to a year ago, further supporting the weak demand claim. Sarepta (SRPT) shares plunge by over 40% after one of its gene therapy treatment trials showed little to no improvements over a placebo. While the medication was not complete, companies involved with Sarepta's development of the drug — Roche (ROG.SW) and Catalent (CTLT) — are also down on the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.","url":"https://finance.yahoo.com/video/nvidia-caterpillar-sarepta-trending-tickers-201915267.html"},{"category":"company","date":1698782822,"headline":"Sarepta Crashes 37% After Its Gene Therapy Flops Its Biggest-Ever Test","id":123529007,"image":"https://media.zenfs.com/en/ibd.com/dd707f3d9f0dce61f930bf64c0195ea5","symbol":"SRPT","publisher":"Yahoo","summary":"Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.","url":"https://finance.yahoo.com/m/f044bd5e-9736-3773-baf7-b18a614d5ff5/sarepta-crashes-37%25-after-its.html"},{"category":"company","date":1698778980,"headline":"Sarepta Therapeutics Stock Dives After New Gene Therapy Data","id":123529008,"image":"https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8","symbol":"SRPT","publisher":"Yahoo","summary":"Sarepta Therapeutics unveiled new data for its gene therapy to treat Ducchenne muscular dystrophy on Monday. Shareholders aren’t happy: The stock is down 40% in late-Tuesday trading. The company said that patients treated with Elevidys showed increased motor function, compared to patients who received placebos at 52 weeks.","url":"https://finance.yahoo.com/m/34b7d75c-2a24-3ad0-95dd-28fd3426cd03/sarepta-therapeutics-stock.html"},{"category":"company","date":1698767526,"headline":"Why Sarepta Therapeutics Stock Is Crashing Today","id":123529010,"image":"https://s.yimg.com/ny/api/res/1.2/UC41i31GQIo05RNVFUgbzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/5b294cde64f3149cf047c69d4c6603bc","symbol":"SRPT","publisher":"Yahoo","summary":"Shares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 43.6% lower as of 11:10 a.m. ET on Tuesday.  The huge sell-off came after the company announced top-line results from its phase 3 Embark study evaluating Elevidys in treating young patients with Duchenne muscular dystrophy (DMD).  Why did Sarepta's CEO sound so upbeat?","url":"https://finance.yahoo.com/m/ef9c2581-24d4-3d53-bcad-974e058e2921/why-sarepta-therapeutics.html"},{"category":"company","date":1698762511,"headline":"Sarepta Stock Tanks As DMD Gene Therapy Fails Confirmatory Study, Risks Market Withdrawal","id":123525837,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405176819/image_1405176819.jpg?io=getty-c-w1536","symbol":"SRPT","publisher":"SeekingAlpha","summary":"Sarepta Therapeutics faces uncertainty as its gene therapy drug ELEVIDYS fails to meet primary endpoint. Check out if SRPT stock is a buy, sell, or hold now.","url":"https://seekingalpha.com/article/4645497-sarepta-stock-tanks-dmd-gene-therapy-fails-confirmatory-study-risks-market-withdrawal"},{"category":"company","date":1698762360,"headline":"Sarepta Stock Sinks 43% on Uncertain Future for Its Gene Therapy","id":123529011,"image":"https://s.yimg.com/ny/api/res/1.2/x0JRoGhww4HUVc0SWsfYHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/770f64e2d48fc0abbf88dce508946399","symbol":"SRPT","publisher":"Yahoo","summary":"In a trial of gene therapy Elevidys, patients on the drug didn't show a statistically significant improvement over patients who received a placebo in the primary measure used.","url":"https://finance.yahoo.com/m/eee46d29-d04c-3890-88cd-514196effce6/sarepta-stock-sinks-43%25-on.html"},{"category":"company","date":1698757140,"headline":"Lyft downgraded, Roku upgraded: Wall Street's top analyst calls","id":123524823,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187403316"},{"category":"company","date":1698756478,"headline":"Sarepta's Elevidys: Secondary Outcomes Hold Regulatory Promise","id":123523207,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/177141761/image_177141761.jpg?io=getty-c-w1536","symbol":"SRPT","publisher":"SeekingAlpha","summary":"Sarepta's Elevidys missed primary endpoint but showed strong secondary outcomes. Read more to see our analysis on SRPT stock.","url":"https://seekingalpha.com/article/4645422-sareptas-elevidys-secondary-outcomes-hold-regulatory-promise"},{"category":"company","date":1698755880,"headline":"Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session","id":123524280,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187370079"},{"category":"company","date":1698755460,"headline":"EVER, BIVI and CNTG among mid-day movers","id":123526111,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187358931"},{"category":"company","date":1698751560,"headline":"What You Missed On Wall Street This Morning","id":123522438,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187253018"},{"category":"company","date":1698751440,"headline":"Catalent designated as 'bullish Fresh pick' at Baird with pullback 'overdone'","id":123522441,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187250167"},{"category":"company","date":1698745620,"headline":"Why Are Stocks Down Today?","id":123522442,"image":"","symbol":"SRPT","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187097400"},{"category":"company","date":1698743340,"headline":"BB Stock Alert: What to Know as BlackBerry Announces CEO Departure","id":123522444,"image":"","symbol":"SRPT","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187037829"},{"category":"company","date":1698743340,"headline":"Biggest stock movers today: Caterpillar, Arista Networks, BP, Pinterest and more","id":123522443,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187038109"},{"category":"company","date":1698743040,"headline":"Sarepta Therapeutics, Petmed Express among healthcare movers","id":123522445,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187031335"},{"category":"company","date":1698742740,"headline":"Cantor downgrades Sarepta on uncertainties after study miss","id":123522446,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187022885"},{"category":"company","date":1698742620,"headline":"US Stocks Fall; Pfizer Swings To Q3 Loss","id":123521732,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187020330"},{"category":"company","date":1698742440,"headline":"Sarepta downgraded to Neutral from Overweight at Cantor Fitzgerald","id":123522449,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187016199"},{"category":"company","date":1698741780,"headline":"Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?","id":123522450,"image":"","symbol":"SRPT","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186998147"},{"category":"company","date":1698741420,"headline":"Sarepta price target lowered to $148 from $217 at RBC Capital","id":123522451,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186991292"},{"category":"company","date":1698740700,"headline":"Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal ","id":123564210,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SRPT","publisher":"MarketWatch","summary":"Company plans to seek label expansion for Duchenne muscular dystrophy treatment","url":"https://www.marketwatch.com/story/sarepta-therapeutics-shares-plunge-as-gene-therapy-trial-falls-short-of-primary-goal-baf4734e"},{"category":"company","date":1698740520,"headline":"Morning Brew: Mixed Reviews for Apple's New Macs, Arista Networks Soars, and Sarepta Therapeutics","id":123522452,"image":"","symbol":"SRPT","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186968188"},{"category":"company","date":1698740280,"headline":"Sarepta in selloff after late-stage setback for Duchenne candidate","id":123522252,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186963471"},{"category":"company","date":1698740280,"headline":"Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket","id":123521762,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186964306"},{"category":"company","date":1698739620,"headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","id":123521733,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186947889"},{"category":"company","date":1698738780,"headline":"Fly Intel: Pre-market Movers","id":123522456,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186928108"},{"category":"company","date":1698738600,"headline":"5 stocks to watch on Tuesday: Sarepta Therapeutics, Pfizer, AMD and more","id":123522457,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186923751"},{"category":"company","date":1698737940,"headline":"Morgan Stanley says Sarepta commentary points to minimal Catalent impact in FY24","id":123522256,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186908754"},{"category":"company","date":1698737580,"headline":"KXIN and ICU among pre-market losers","id":123522258,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186900977"},{"category":"company","date":1698737400,"headline":"S\u0026P 500 Futures Up in Premarket Trading; Sarepta Therapeutics, Lattice Semiconductor Lag","id":123525381,"image":"https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png","symbol":"SRPT","publisher":"MarketWatch","summary":"With U.S. stock markets set to open in two hours, (PINS) was up 16.5% in pre-market trading, and (ANET) was up 10.7%. (ZBRA), (NYCB), and (GPN) were all...","url":"https://www.marketwatch.com/articles/s-p-500-futures-up-in-premarket-trading-sarepta-therapeutics-lattice-semiconductor-lag-02d326cf"},{"category":"company","date":1698737220,"headline":"Oppenheimer downgrades Sarepta to Perform as EMBARK misses primary endpoint","id":123522461,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186892366"},{"category":"company","date":1698737160,"headline":"Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal","id":123522462,"image":"","symbol":"SRPT","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186890279"},{"category":"company","date":1698735600,"headline":"Pinterest To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Tuesday","id":123521767,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186859924"},{"category":"company","date":1698732840,"headline":"JPMorgan cuts Sarepta target, removes from Analyst Focus List","id":123522466,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186803807"},{"category":"company","date":1698731940,"headline":"Sarepta price target lowered to $164 from $186 at BofA","id":123522467,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186787702"},{"category":"company","date":1698731640,"headline":"Sarepta downgraded to Perform from Outperform at Oppenheimer","id":123522469,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186783084"},{"category":"company","date":1698730860,"headline":"Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), GeneDx Holdings (WGS) and Protalix (PLX)","id":123522470,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186769952"},{"category":"company","date":1698730560,"headline":"Sarepta price target lowered to $136 from $202 at Baird","id":123522471,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186765657"},{"category":"company","date":1698727620,"headline":"Bank of America Securities Reaffirms Buy Rating for Sarepta Therapeutics Amid Promising EMBARK Trial Results for Elevidys in DMD Treatment","id":123522472,"image":"","symbol":"SRPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186722785"},{"category":"company","date":1698727260,"headline":"Sarepta Therapeutics Q3 2023 Earnings Preview","id":123557481,"image":"","symbol":"SRPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187794796"},{"category":"company","date":1698726780,"headline":"These Stocks Are Moving the Most Today: Caterpillar, JetBlue, Sarepta, Catalent, Lattice, Pinterest, Wolfspeed, and More","id":123527708,"image":"https://images.barrons.com/im-356352/social","symbol":"SRPT","publisher":"MarketWatch","summary":"Caterpillar smashes earnings estimates but the stock falls, JetBlue slumps after the carrier says it expects a fourth-quarter loss wider than Wall Street...","url":"https://www.marketwatch.com/articles/stock-market-movers-9b8fe0ff"},{"category":"company","date":1698723600,"headline":"What You Missed On Wall Street On Tuesday","id":123529395,"image":"","symbol":"SRPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187679717"},{"category":"company","date":1698718200,"headline":"What's Going On With Biotech Contract Service Firm Catalent Stock Today?","id":123551631,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187523161"},{"category":"company","date":1698716280,"headline":"Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss","id":123557484,"image":"","symbol":"SRPT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187469661"}]}